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Abstract
Antimitochondrial antibodies (AMA) are the serum hallmark of primary biliary cirrhosis (PBC). However, AMA-positivity
can be found in non-PBC sera when lower dilutions are used, thus raising issues about the speciﬁcity and sensitivity of the test.
AMA reacts primarily with the lipoylated domains of pyruvate dehydrogenase-E2 (PDC-E2) which is highly conserved across
species, including bacteria. We studied 77 serum samples, including 24 from patients with anti-PDC-E2-positive PBC and 53
controls (16 with autoimmune hepatitis (AIH), 10 with primary sclerosing cholangitis (PSC), and 27 healthy individuals) for
their reactivities at serial dilutions (1:10, 1:20 and 1:40) against Escherichia coli DH5 alpha lysate overexpressing human PDC-
E2 using immunoblotting (IB). A murine anti-human PDC-E2 monoclonal antibody (mAB) was used as control. We further
studied positive sera using adsorption with a synthetic E. coli peptide sharing similarity with human PDC-E2. Finally, we
veriﬁed whether a unique buffer for E. coli preparation could reduce non-speciﬁc serum reactivity. Results demonstrated that
100% of anti-PDC-E2-positive PBC and up to 38% of control sera at 1:10 dilution recognized E. coli PDC-E2 at IB while
dilution tests indicated that the overall potency of PBC reactivity was 100-fold higher compared to controls. In fact, a
subgroup (20–38%) of non-PBC sera were positive at low titers but lost the reactivity when absorbed with the synthetic E. coli
peptide. Finally, our unique buffer reduced the reactivity of non-PBC sera as measured by ELISA. In conclusion, we
demonstrated that weak cross-reactivity with E. coli PDC-E2 occurs in non-PBC sera at lower dilutions and that such
reactivity is not due to AMA-positivity. The use of a speciﬁc buffer might avoid the risk of false positive AMA determinations
when E. coli-expressed recombinant antigens are used.
Keywords: Escherichia coli, autoantibodies, speciﬁcity, cross-reactivity
Abbreviations: AMA, antimitochondrial antibodies; PBC, primary biliary cirrhosis; AIH, autoimmune hepatitis; PSC,
primary sclerosing cholangitis; NC, normal control; PDC-E2, pyruvate dehydrogenase complex-E2; IIF, indirect
immunoﬂuorescence; BHM, bovine heart mitochondria; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis;
mAb, monoclonal antibody; OD, optical density; E3BP, E3 binding protein; TLR, toll-like receptors
High-titer antimitochondrial autoantibodies (AMA)
are the serum hallmark of primary biliary cirrhosis
(PBC) (Leung et al. 1997). The major AMA
autoantigens belong to the 2-oxo dehydrogenase
enzymecomplex familywithmostpatient serareacting
against the lipoylated domains of the pyruvate
dehydrogenase complex-E2 (PDC-E2) (Gershwin
et al. 1987; Coppel et al. 1988). Interestingly, the
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served across species (Fussey et al. 1990), thus
suggesting that molecular mimicry by bacterial
homologs might lead to AMA appearance (Van de
Water et al. 2001). In fact, AMA cross-reactivity with
non-humanmitochondrialproteinssuch as Escherichia
coli PDC-E2 occurs based on amino acid sequence
similarity (Fussey et al. 1990). In the past years, new
laboratory techniques have increased the sensitivity
and speciﬁcity of AMA testing, particularly when
recombinant mitochondrial antigens overexpressed in
E. coli are used (Moteki et al. 1996; Miyakawa et al.
2001).In some cases, however,the use of recombinant
antigenscanpotentiallyleadtoAMA-positivityinnon-
PBC samples, particularly when lower serum dilutions
are used, thus possibly limiting the speciﬁcity of the
assay. Deﬁning these non-PBC reactivities and ﬁnding
a way to avoid false positive results appears critical to
maximize the diagnostic power of AMA
determination.
We hypothesized that non-PBC reactivities with
lysates from E. coli overexpressing recombinant
PDC-E2 might be secondary to low-afﬁnity antibody
binding to bacterial proteins, rather than the over-
expressed human motif. We observed that reactivity
against PDC-E2, either human or bacterial, could be
found in a subgroup of non-PBC sera. However,
reactivity was absent after adsorption of non-PBC
sera with a bacterial synthetic peptide or following
the use of a speciﬁc E. coli buffer, thus ultimately
indicating novel ways to increase the sensitivity of
AMA testing, recapitulating the extreme speciﬁcity
of the AMA when human recombinant antigens
are used.
Materials and methods
Subjects
Sera from non-PBC (n ¼ 53) and PBC (n ¼ 24)
individuals were studied. Non-PBC sera included 16
patients with autoimmune hepatitis (AIH), 10 with
primary sclerosing cholangitis (PSC), and 27 normal
controls (NC). The diagnoses of AIH, PSC and
PBC were based on internationally accepted criteria
(Wiesner et al. 1985; Alvarez et al. 1999; Talwalkar
and Lindor 2003). Brieﬂy, all patients in the PBC
group underwent liver biopsy and the diagnosis was
made when two out of three criteria (i.e. presence of
serum AMA $ 1:40, elevated serum alkaline phos-
phatase, and compatible liver histology) were met.
Importantly, no histological features of other liver
diseases (i.e. overlap syndromes) were observed in
our PBC group. All sera were tested at serial
dilutions for AMA using indirect immunoﬂuores-
cence (IIF) on rodent tissue sections and then by
immunoblotting (IB) using bovine heart mitochon-
dria (BHM) as previously described.
Expression of recombinant PDC-E2 and preparation
of E. coli lysate
E. coli DH5 alpha was used as the vector to
overexpress the recombinant human PDC-E2 protein
(Moteki et al. 1996) and bacterial lysates were
prepared as previously described (Eley et al. 1972).
Brieﬂy,plasmidDNA(PGEX-4T)wasaddedtoE.coli
DH5 alpha competent cells, which were dissolved on
ice and mixed. After heat shock treatment (428C for
30s), sterile SOC medium was added to the culture
followed by shaking, and cells were then seeded on LB
agar plate. After transformation, the cultured E. coli
was rinsed, then frozen and fused several times,
sonicated eight times for 30s and centrifuged at
15,000rpm to obtain the supernatant. The ﬁnal
p r o t e i nc o n c e n t r a t i o ni nt h es u p e r n a t a n tw a s
32.1mg/dl as measured by Bradford Protein Assay
(Bio-Rad, Hercules, CA, USA).
SDS-PAGE and immunoblotting
The E. coli DH5 alpha lysates (100ml/lane) were
separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) (Laemmli 1970) and
then transferred onto a polyvinylidene diﬂuoride
(PVDF) membrane. Sera were tested at 1:100,
1:1000 and 1:10,000 dilutions in PBS containing
0.1% Tween 20 as previously described (Towbin et al.
1979). Peroxydase-conjugated goat anti-human IgG,
A and M (MBL, Nagoya, Japan) was used at 1:3000
dilutions as secondary antibody. The murine mono-
clonal antibody (mAb) C355.1 speciﬁc for the inner
lipoylated domain of human PDC-E2 (Migliaccio
et al. 1998, 2001) was used as positive control
throughout the study. Known negative sera were also
included in all experiments.
Preparation of the synthetic peptide for serum adsorption
A comparison of PDC-E2 protein sequences in
humans and from E. coli DH5 alpha indicated that
two regions of human PDC-E2 (amino acids 36–49
and 163–176) include amino acid similarity with one
region in the bacterial homolog (amino acids 31–44)
(Figure 1); we then synthesized a peptide spanning
E. coli PDC-E2 amino acids 31–44. The synthetic
peptide was used at 1mg/dl ﬁnal concentration to
Figure 1. Amino acid sequence homology between human PDC-
E2 and homologs from E. coli DH5 alpha. It is of note that the
human sequences are also included in the triple expression hybrid
pMIT3 that was used herein for AMA–ELISA.
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previously shown to react with PDC-E2 at IB. After
adsorption (overnight at 48C) sera were tested against
E. coli lysates at IB at equivalent concentrations.
Use of a unique E. coli buffer in ELISA assay for AMA
Serum samples (n ¼ 45) from 20 patients with PBC
and 25 non-PBC subjects were further studied at
1:1000 dilution for AMA using the triple expression
hybrid clone pMIT3 as previously described (Miya-
kawa et al. 2001). Sera were tested using ELISA with
and without the unique buffer (Miyakawa et al. 2001)
and optical density (OD) values calculated and
compared. Based on our previous data (Miyakawa
et al. 2001), the OD value threshold for determining
the AMA status was set at 0.130.
Statistical analysis
Group data were compared by the Welch’s t-test and
paired t-test. Statistical comparisons were made using
SAS software (SAS Institute Inc., Cary, NC, USA).
All analyses were two-sided, and P values of ,0.05
were considered statistically signiﬁcant.
Results
AMA
Sera were tested for AMA using IIF at 1:10, 1:20 and
1:40 dilutions and IB against BHM at 1:100 dilution.
Anti-PDC-E2-positivity at IB was considered as a
reactivity against the characteristic 74kDa band.
Results of AMA testing are shown in Table I. Twenty
four/24 (100%) PBC sera presented an AMA-speciﬁc
IIF pattern at 1:40 while 22/24 (92%) were also anti-
PDC-E2 positive at IB. Among non-PBC sera, 10/16
(63%) AIH, 8/10 (80%) PSC and 20/27 (74%) NC
were negative for IIF–AMA at all dilutions or at IB.
On the other hand, 6/16 (37%) AIH, 2/10 (20%) PSC
and 7/27 (26%) NC were found positive for AMA–
IIF at 1:10 dilution and negative at IB. Among these,
one AIH serum was positivefor IIF–AMA also at 1:20
dilution.
Immunoreactivity against E. coli DH5 alpha lysate
We investigated the immunoreactivity of sera against
E. coli DH5 alpha lysate by IB. Sera were diluted at
1:100 in PBS and 24/24 (100%) PBC sera recognized
one or both of two proteins of 74 and 52kDa
molecular weight. In particular, 23/24 PBC sera
reacted with the 74 and 52kDa proteins. Among
control sera, 6/16 (38%) AIH, 2/10 (20%) PSC and
8/27 (30%) NC also reacted with either one or both
proteins. It is of note that all but one NC non-PBC
sera reacting with E. coli lysate were also positive for
low titer AMA (#1:20) by IIF. The results observed at
IB are summarized in Table II and representative
results for tested sera are shown in Figure 2B.
Speciﬁcity of anti-PDC-E2
The anti-human PDC-E2 C355.1 murine mAb was
tested against the E. coli DH5 alpha lysate at IB for the
deﬁnition of bands. As shown in Figure 2A, this
antibody reacted with both 74 and 52kDa proteins.
Dilution tests
Dilution tests were performed to compare the
immunoreactivity of PBC and non-PBC sera at IB
against E. coli DH5 alpha lysate overexpressing human
PDC-E2. Test sera previously showing reactivity at
1:100 were serially diluted up to 1:10,000 in PBS.
Twenty-two/24 (92%) PBC sera still reacted against
the 74 and/or 52kDa proteins at 1:10,000 dilution
Table I. AMA patterns of studied PBC and non-PBC sera analyzed by indirect IIF and IB with BHM. Anti-PDC-E2 positivity at IB was
determined as the reactivity against the characteristic 74kDa protein. Continuous variables are expressed as mean ^ standard error.
Female sex (n) Age (years)
AMA
IIF
74kDa* IB
Negative 1:10 1:20 .1:40
AIH (n ¼ 16) 14/16 56 ^ 8 10 (63%) 5 (31%) 1 (6%) 0 0
PSC (n ¼ 10) 1/10 54 ^ 7 8 (80%) 2 (20%) 0 0 0
NC (n ¼ 27) 10/27 34 ^ 8 20 (74%) 7 (26%) 0 0 0
PBC (n ¼ 24) 21/24 56 ^ 8 – – – 24 (100%) 22 (92%)
Table II. Serial dilution analysis of PBC and non-PBC sera at IB
for anti-PDC-E2 reactivity against E. coli DH5 alpha lysate.
Serum dilution
1:100 1:10,000
74kDa
(+)
52kDa
(+)
74- and/or 52kDa
(+)
AIH (n ¼ 16) 6 (38%) 6 (38%) 6 (38%) 1 (6%)
PSC (n ¼ 10) 1 (10%) 1 (10%) 2 (20%) 0
NC (n ¼ 27) 3 (11%) 5 (19%) 8 (30%) 0
PBC (n ¼ 24) 23 (96%) 23 (96%) 24 (100%) 22 (92%)
AMA speciﬁcity 291whereas the reactivities of non-PBC sera were lost at
1:10,000 in all controls but 1/16 AIH sample
(Table II). Two representative patterns of dilution
tests for one PBC and one NC sera are shown in
Figure 3.
Inhibition tests of E. coli DH5 alpha PDC-E2 synthetic
peptide
Following absorption with the synthetic bacterial
peptide, 23/24 PBC sera still reacted against the 74
and/or 52kDa proteins from the E. coli DH5 alpha
lysate at 1:100 dilution. On the contrary, such
reactivity was absent at the same dilution after
adsorption in 15/16 (94%) previously positive non-
PBC sera. The results of two representative adsorp-
tion experiments (one PBC and one NC sera) are
shown in Figure 4.
Efﬁcacy of a unique E. coli buffer for AMA ELISA testing
To investigate the effects of our unique E. coli buffer
on ELISA assays for AMA testing we compared OD
values obtained at ELISA with and without the buffer.
Figure 5 illustrates the changes in OD values between
the two conditions. PBC sera (n ¼ 20) produced
similar OD values when the buffer was added
(2.187 ^ 0.047 vs. 2.299 ^ 0.046 without the buffer,
P ¼ NS). Interestingly, when non-PBC sera (n ¼ 25)
were used, the addition of our E. coli buffer led to
signiﬁcantly lower OD values (0.031 ^ 0.014 vs.
0.161 ^ 0.005 without the buffer; P , 0.001). In 14
non-PBC sera, OD values obtained without the buffer
were above the determined threshold and were
therefore to be considered as AMA-positive. When
our E. coli buffer was used, on the contrary, the
decrease in OD values led to AMA-negativity in all 14
cases. Conversely, no change in AMA status was
observed among PBC sera.
Discussion
The accurate deﬁnition of serum AMA reactivities in
patients with PBC is important for several reasons.
First, despite the high sensitivity of AMA testing
obtained with the use of E. coli-expressed recombinant
antigens, the issue of its speciﬁcity remains, particu-
larly when lower serum dilutions are used. Second, it
is still debated whether PBC cases not presenting
serum AMA are in fact lacking such autoantibodies or
are secondary to limitations of the methods that do not
detect low-titer AMA. Third, serum AMA speciﬁc for
PDC-E2 appear to cross-react with bacterial mito-
chondrial antigens (4) while absorption of PBC sera
with bacterial lysates fails to remove reactivities
against mammalian antigens (16). These obser-
vations, alongside with the inhibitory effects of AMA
on enzyme activity in different species (Teoh et al.
1994), are the bases of the mechanisms of molecular
mimicry proposed in the pathogenesis of AMA and
PBC (Van de Water et al. 2001). To conﬁrm this
A: PBC B: NC
pre post pre post
E.coli DH5 alpha
PDC-E2 peptide
74-kDa
52-kDa
0 1 0 1 mg/mL
Figure 4. Adsorption tests. Sera were tested at IB after
preincubation with the synthetic E. coli peptide. Reactivities with
the 74 and 52kDa proteins were visible after adsorption of the PBC
serum (panel A) while reactivities were lost in the NC serum
(panel B).
Figure 3. Dilution tests. Patterns observed with different serum
dilutions of one PBC (panel A) and one NC serum (panel B) are
shown. We note that the PBC serum reacts with the 74 and 52kDa
proteins at 1:10,000 dilution while reactivities were lost at 1:1000
for NC.
Figure 2. Representative IB pattern against E. coli DH5 alpha
lysate overexpressing human PDC-E2 showing the 74 and 52kDa
reacting proteins. Results obtained with the murine anti-human
PDC-E2 monoclonal antibody C355.1 (panel A), 2 anti-PDC-E2-
positive PBC sera (lanes 1 and 2), 2 (AIH) sera (lanes 3 and 4), 2
PSC sera (lanes 5 and 6), and 2 NC sera (lanes 7 and 8) are depicted
(panel B). Reactivities against the 74 (lanes 1–5 and 7) and 54kDa
(lanes 1–4, 6 and 8) proteins are shown.
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between cross-reactivities and independent humoral
responses directed against similar proteins from
different species, namely human and bacterial
PDC-E2.
We report herein that AMA patterns detected when
non-PBC sera are tested at IB with lysates of E. coli
overexpressingrecombinanthumanPDC-E2areinfact
due to reactivities against bacterial rather than human
proteins. Conversely, reactivities of PBC sera are
directed at human antigens. Moreover, we suggest that
the useofourE.colibuffercan signiﬁcantlyincreasethe
speciﬁcity of the technique for AMA testing while not
reducing its sensitivity, thus suggesting novel ways to
perform routine serum analysis.
We conﬁrmed that PBC sera react with two proteins
from E. coli DH5 alpha lysate. The nature of the bands
of 74 and 52kDa reacting with PBC sera at IB was
deﬁned using the validated murine anti-human PDC-
E2 mAb C355.1 that reacted with both proteins. The
deﬁnition of the band of lower molecular weight
warrants further discussion since it could be mis-
takenly attributed to the cross-reacting E3 binding
protein (E3BP, formerly protein X) (Dubel et al.
1999). Previous data from our group, however,
demonstrated that C355.1 mAb does not cross-react
with E3BP (Migliaccio et al. 1998); therefore, we
considered that both bands corresponded to PDC-E2.
We also report that 20–38% of non-PBC sera
included in our study also reacted with both bands
from the bacterial lysate when lower dilutions were
used. Experiments based on serial serum dilutions
demonstrated that non-PBC reactivity was 100-fold
lower compared to PBC. Although based on limited
evidence, low-titer AMA reactivity to mitochondrial
antigens in non-PBC sera should be regarded as a
relatively common ﬁnding, more often limited to IIF
testing, in patients with autoimmune diseases other
than PBC as well as in healthy subjects. To better
deﬁne the nature of these weak reactivities we
hypothesized that native bacterial rather than over-
expressed human proteins might be the target of the
antibody response in non-PBC sera. Data from
our adsorption experiments using a synthetic E. coli
peptide conﬁrmed our working hypothesis. In fact, the
IB pattern of PBC sera did not change after
adsorption, while in all non-PBC sera but one from
a patient with AIH reactivity was lost.
We then attempted to reduce ELISA non-speciﬁc
antibody binding using our E. coli buffer. Interest-
ingly, the addition of this buffer allowed a signiﬁcant
reduction in the reactivity of non-PBC sera while
PBC reactivities were not affected. In particular, all
14 non-PBC sera presenting OD values exceeding the
established threshold became AMA negative with the
use of the E. coli buffer, thus proving to be most likely
false AMA positive. The adsorption with the
synthetic peptide might also be used to achieve
similar results; however, an analysis of costs and
effectiveness would easily prove that the use of our
unique E. coli buffer is preferable to improve the
speciﬁcity of AMA testing. In fact, ELISA is a well-
established validated method for sensitive testing of
AMA using recombinant antigens and should be
regarded as a less expensive approach. Finally, we
note that the hypotheses presented herein will beneﬁt
from additional studies on large populations of sera
from patients with IIF–AMA-negative PBC or with
recurrent urinary tract infections that will further
deﬁne both sensitivity and speciﬁcity of the proposed
AMA testing methods. However, we submit that our
data have signiﬁcant potential implications for AMA
testing in clinical practice, by allowing higher
sensitivity and speciﬁcity with the use of recombinant
mitochondrial proteins rather than native proteins
(Miyakawa et al. 2001).
Figure 5. Comparison of OD values with and without our unique E. coli buffer for AMA–ELISA using the triple hybrid antigen pMIT3.
Mean OD valueswere not different with the buffer for PBC sera (n ¼ 20) while they were signiﬁcantlylower when the buffer was used for non-
PBC sera (n ¼ 25). The OD threshold value (0.130) is represented in the right panel.
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larly bacteria) and xenobiotics might play a role in the
initiation of the autoimmune reaction in PBC. Among
bacteria, most evidence has been collected for E. coli,
mostly based on the reported higher prevalence of
recurrent urinary tract infections among patients with
PBC (Gershwin et al. 2005). Additionally, microor-
ganisms may contribute to autoimmunity via a
polyclonal antibody activation and possibly the release
of isolated antigens that could in turn activate the
innate immune cascade. Bacterial molecules such as
lipopolysaccharide (LPS) or CpG might then play a
role as modulators of the immune response, as
demonstrated by our group in serum hyper-IgM
associated with PBC (Kikuchi et al. 2005), mediated
by the binding to toll-like receptors (TLR) on
macrophages and dendritic cells (Kaisho and Akira
2000, 2002). TLR might then activate innate
immunity cells and stimulate the release of pro-
inﬂammatory cytokines that in turn contribute to
activate latent autoreactive T cells. The implications
of our ﬁndings in this scenario are still largely
unknown; however, we can submit some observations.
First, we demonstrated that reactivity to bacterial
mitochondrial antigens, albeit at low-titers, can be
observed also in non-PBC sera, thus supporting the
role of other infectious agents such as Novosphingo-
bium aromaticivorans (Selmi et al. 2003). Second, we
conﬁrm that the occurrence of such AMA-like
reactivity alone is unlikely to be sufﬁcient at inducing
PBC in healthy individuals. To initiate autoimmunity
and perpetuate the immune-mediated tissue-speciﬁc
injury that is PBC, in fact, additional immunological
requirements must be met, most likely also based on a
susceptible genetic background. As indicated by the
high concordance in monozygotic twins (Selmi et al.
2004), in fact, the weight of genetic factors in
determining susceptibility to PBC cannot be
overlooked.
In conclusion, despite the lack of clinical association
so far reported for AMA titers, we submit that an
additional effort should be dedicated at deﬁnining the
pathogenicityof these highlyspeciﬁc autoantibodies to
unravel the enigmatic immunopathogenesis of PBC,
possibly using animal models.
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